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Background: Our objective was to develop a tool to identify patients with COPD for proactive 
palliative care. Since palliative care needs increase during the disease course of COPD, the 
prediction of mortality within 1 year, measured during hospitalizations for acute exacerbation 
COPD (AECOPD), was used as a proxy for the need of proactive palliative care.
Patients and methods: Patients were recruited from three general hospitals in the Netherlands 
in 2014. Data of 11 potential predictors, a priori selected based on literature, were collected 
during hospitalization for AECOPD. After 1 year, the medical files were explored for the date of 
death. An optimal prediction model was assessed by Lasso logistic regression, with 20-fold cross-
validation for optimal shrinkage. Missing data were handled using complete case analysis.
Results: Of 174 patients, 155 patients were included; of those 30 (19.4%) died within 1 year. 
The optimal prediction model was internally validated and had good discriminating power 
(AUC =0.82, 95% CI 0.81–0.82). This model relied on the following seven predictors: the 
surprise question, Medical Research Council dyspnea questionnaire (MRC dyspnea), Clinical 
COPD Questionnaire (CCQ), FEV
1
% of predicted value, body mass index, previous hospital-
izations for AECOPD and specific comorbidities. To ensure minimal miss out of patients in 
need of proactive palliative care, we proposed a cutoff in the model that prioritized sensitivity 
over specificity (0.90 over 0.73, respectively). Our model (ProPal-COPD tool) was a stronger 
predictor of mortality within 1 year than the CODEX (comorbidity, age, obstruction, dyspnea, 
and previous severe exacerbations) index.
Conclusion: The ProPal-COPD tool is a promising multivariable prediction tool to identify 
patients with COPD for proactive palliative care.
Keywords: COPD, exacerbation, proactive palliative care, prognosis, mortality
Introduction
COPD is a progressive life-threatening lung disease.1 During the disease course, the 
need for disease-oriented care remains unchanged while the need for proactive pallia-
tive care increases for patients with COPD.2 Proactive palliative care, which includes 
advance care planning (ACP) conversations, is intended to improve the quality of life 
and quality of care.3,4 However, for patients with COPD, such care is not yet common.2,5 
An important barrier is the identification of patients with COPD who might benefit 
from proactive palliative care.2
Identification for proactive palliative care is complicated by the unpredictable 
disease course of COPD.6 Stable phases in the disease course are interrupted by acute 
exacerbations; any one of which may be fatal.6 Although, general tools to identify 
patients for palliative care exist, they are not specifically intended or validated for the 
identification of patients with COPD.7,8 In addition, models of survival in stable COPD 
have been developed to be able to adjust and optimize care.9,10 Unfortunately, these 
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population models are of limited value to predict survival for 
individual patients.11 This prognostic difficulty has led to a 
discussion among clinicians whether or not a transition point 
for the initiation of proactive palliative care exists.12–15 Some 
clinicians argue that more specific criteria of end-stage COPD 
need to be explored.13 Others argue that, since such criteria 
may not exist, searching further may lead to prognostic 
paralysis.14,15 Instead, they promote early integration of pallia-
tive care according to needs.15 The focus in this discussion has 
been on whether or not we can accurately predict mortality 
instead of the intended objective, identifying patients with 
COPD in need of proactive palliative care. Since palliative 
care needs increase during the disease course of COPD,2 the 
prediction of mortality can be used as a proxy for the need 
of palliative care. To ensure minimal miss out of patients in 
need of such care, this tool should have a sensitivity near 
100 with specificity as high as possible.
Hospitalizations for an acute exacerbation COPD 
(AECOPD) are associated with significant mortality and 
therefore create an opportunity to identify patients with poor 
prognosis in need of palliative care.16 Recently, potential 
relevant variables have been identified to predict posthospital 
mortality in patients hospitalized for an AECOPD.16,17 This 
is the first prospective study to incorporate these variables 
with the objective to develop a multivariable prediction tool 
(the ProPal-COPD tool) to identify patients with COPD in 
need of proactive palliative care. Our objective was to assess 
the discriminating power of a set of indicators for proactive 
palliative care in predicting death for any cause within 1 year. 
This outcome was used as a proxy for the potential need of 
proactive palliative care in patients with COPD.
Patients and methods
source of data
Data for prognostic accuracy testing in patients hospitalized 
for an AECOPD were obtained from the PROLONG 
study.18 This prospective pragmatic cluster controlled trial 
was performed in six general hospitals in the Netherlands; 
of those, three were in the intervention condition and three 
in the control condition. All recruited patients hospitalized 
for an AECOPD received usual care, while only patients in 
the intervention condition with poor prognosis additionally 
received proactive palliative care. In this trial, poor prog-
nosis was defined as meeting two or more predictors of a 
set of 11 predictors of poor prognosis. For the prognostic 
accuracy study, described in this study, we only used data 
of those patients recruited from the three hospitals in the 
control condition.
Participants
We screened for potential participants in three general 
hospitals in the Netherlands from January 14, 2014, to 
December 29, 2014. All patients with the clinical diagnosis of 
COPD and hospitalized for an AECOPD who were 18 years 
or older were eligible. An AECOPD was defined as “an acute 
worsening of the patient’s condition from the stable state, 
which is sustained and may warrant the patient to seek addi-
tional treatment.”19 Since the severity of airway obstruction 
and spectrum of pathogens in pneumonic and non-pneumonic 
exacerbations are similar,20 patients with COPD who had 
been hospitalized for an acute pneumonia accompanied by 
increased sputum and dyspnea were also included. Patients 
who did not speak Dutch or had a severe cognitive disorder 
were excluded from participation. All patients received usual 
care for an AECOPD and the period thereafter.
The study was approved by the Medical Ethics 
Committee (METC) of the Radboud University Medical 
Center, Nijmegen (METC protocol number 2012/260). 
Thereafter, we requested and received research approval 
from all three participating hospitals. All participants gave 
written informed consent before enrollment.
Outcome
The outcome measure was death for any cause within 1 year. 
This outcome measure was used as a proxy for the potential 
need of proactive palliative care. To ensure minimal miss 
out of patients in need of such care, we were looking for a 
tool with a sensitivity near 100% and a specificity as high 
as possible.
Predictors
All 11 predictors are presented in Table 1. Each of them is a 
categorical variable indicating whether or not the participant 
meets the specific criteria for this predictor. References with 
the rationale to include the predictor in the multivariable 
prediction model are also presented in Table 1. Patients 
filled out demographics, the Medical Research Council 
dyspnea questionnaire (MRC dyspnea) and the Clinical 
COPD Questionnaire (CCQ) on the sixth day of hospital 
stay or in case the patient was discharged earlier on the day 
before leaving the hospital. The MRC dyspnea is a ques-
tionnaire used for grading the effect of breathlessness on 
daily activities.27 The patient’s dyspnea score is rated from 
1 to 5, and higher scores represent a more severe dyspnea. 
The patient was asked to rate the dyspnea severity as it was 
2 weeks before hospital admission. The CCQ day version 
was used to measure the health status of patients.28 The CCQ 
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consists of 10 questions covering three domains (symptoms, 
functional status and mental state). The maximum total CCQ 
score is 6 and higher scores represent a worse health status. 
The treating pulmonologist thereafter filled out a checklist 
consisting of the remaining nine predictors. A year after the 
last patient was included, the medical files of all participants 
were explored. Variables looked for were as follows: if 
applicable, date of death and missing scores of predictors 
on the checklist. In case of uncertainty about death and/or 
date of death, we contacted the general practitioner (GP) of 
the patient for information.
sample size
In this prospective study, we included all eligible patients 
willing to participate during the year 2014 to maximize the 
power and generalizability of the results.
Missing data
Missing data were handled using complete case analysis. Par-
ticipant data were excluded from the analysis if a participant 
had missing information on any of the potential predictors. 
Possible reasons for missing data were not or incomplete 
filled-out questionnaire by the patient and/or an incomplete 
filled out checklist by the pulmonologist.
statistical analyses
Baseline characteristics were described using frequencies for 
noncontinuous data, mean with SD for continuous variables 
normally distributed and median with interquartile range 
(IQR) for continuous variables not normally distributed. 
The analysis plan consisted of two steps. The first step had a 
descriptive nature and was aimed at exploring the discrimi-
nating power of individual predictors in predicting death for 
any cause within 1 year. For all 11 predictors, the area under 
the curve (AUC), sensitivity and specificity were calculated. 
The goal of the second step was to build an optimal prediction 
model and to assess its predictive performance using internal 
validation. The model was built using a least absolute shrink-
age and selection operator (Lasso) logistic regression model, 
with 20-fold cross-validation for optimal shrinkage.29,30 By 
using the Lasso method, the risk of over-fitting was reduced, 
and at the same time a relatively simple prediction model was 
obtained. Because the performance of our optimal prediction 
model was validated in the same population used to construct 
it, its predictive performance was overestimated (optimism). 
To estimate this optimism, the procedure proposed by 
Steyerberg30 was followed. In short, using bootstrapping, 
500 new populations were created, and a prediction model was 
built for each population in a completely analogous way. The 
predictive performance of the model, as expressed by the AUC, 
in both the bootstrapped population and original population 
was calculated. The mean difference between these two AUC 
values is an estimate of the optimism of our prediction model.
risk groups
No risk groups were created.
Results
Participants
The participant flow diagram is shown in Figure 1. Of all 
174 participants, 155 participants were included in the 
analyses. The characteristics of the study populations are 
presented in Table 2.
Model development
The numbers of participants who met the criteria of each 
predictor are presented in Table 2. In the study population, 
19.4% of the participants (30 of 155) died within 1 year.
Table 1 set of 11 predictors of poor prognosis for patients 
hospitalized for an aeCOPD and the references with the rational 
to include them in the prediction model
Predictors of poor prognosis References
 1. hypoxemia (PaO2 ,8 kPa) or hypercapnia 
(PaCO2 .6 kPa) at discharge
16,17
 2. Treatment of the exacerbation with nIV 21
 3. Patient needs professional home care service for 
personal care after discharge
22
 4. negative answer to the surprise question:
“Would I (as pulmonologist) be surprised if this 
patient would die in the next year?”
23
 5. The diagnosis of a severe comorbidity such as:
a. non-curable malignancy or
b. Cor pulmonale (proven or non-proven) or
c. Proven ChF or
d. Diabetes mellitus with neuropathy or
e. renal failure, clearance ,40 (gFr, ml/min)
17,24
16
16,17
16,17
16,17
 6. CCQ total, day version .3 25
 7. MrC dyspnea =5 16,26
 8. FeV1 (measured before aeCOPD) ,30% 
of predicted
16,17
 9. BMI ,21 or unplanned weight loss (.10% in the 
last 6 months or .5% in last month)
16,17
 10. Previous hospital admissions for aeCOPD (last 
2 years $2 and/or last year $1)
16
 11. age .70 years 16,17
Notes: PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial 
pressure of oxygen.
Abbreviations: aeCOPD, acute exacerbation COPD; BMI, body mass index; CCQ, 
Clinical COPD Questionnaire; ChF, chronic heart failure; FeV1, forced expiratory 
volume in 1 second; GFR, glomerular filtration rate; MRC dyspnea, Medical Research 
Council dyspnea questionnaire; nIV, noninvasive ventilation.
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The discriminating power of individual predictors in 
predicting death within 1 year is presented in Table 3.
Model specification and performance
The optimal prediction model, build using the Lasso method, 
and its predictive performance are presented in Table 4. 
This logistic regression model includes an intercept and the 
weighted sum of the value of each predictor. The weights are 
the regression coefficients (B). The value of each predictor 
is 1 when present and 0 when absent.
A patient can be considered as in need of proactive pallia-
tive care when the total sum of the logistic regression models 
exceeds a certain cutoff point of the model. The choice of 
this cutoff is essentially a trade-off between sensitivity and 
specificity. A popular choice is to choose the cutoff that con-
siders sensitivity and specificity to be of equal importance, so 
maximizing the sum of sensitivity and specificity. In the 
setting of this study, a cutoff that prioritizes sensitivity above 
specificity does make sense. Therefore, we also present the 
cutoff that maximizes the sum of specificity and 1.5 times 
the sensitivity. Possible cutoffs for both choices are presented 
in Table 5.
The receiver operating characteristic (ROC) curve for the 
prediction of death within 1 year with the optimal cutoffs 
considering different trade-offs between sensitivity and 
specificity is shown in Figure 2.
Discussion
This study shows that we were able to develop a promis-
ing multivariable prediction tool to identify patients with 
COPD in need of proactive palliative care, the ProPal-COPD 
tool. Since palliative care needs increase during the disease 
course,2 and hospitalizations for AECOPD are associated 
with significant mortality risk,16 these hospitalizations create 
an opportunity for identification. This is why the prediction 
of death was used as a proxy for the identification of patients 
in need of palliative care. In our study population, 19.4% of 
participants died within 1 year. This number is in line with 
the 1-year mortality rate in other studies investigating patients 
hospitalized for AECOPD.31,32 Our optimal prediction model 
of death within 1 year had good discriminating power; the 
true AUC was 0.82 (95% CI 0.81–0.82), and the estimated 
optimism of 0.05 indicated good internal validity. To ensure 
minimal miss out of patients in need of palliative care, we 
proposed a cutoff in the prediction model that prioritized sen-
sitivity above specificity. This optimal cutoff was -1.36, with 
a sensitivity of 0.90 and a specificity of 0.73. This implies 
that, when used, only 10% of patients in need of palliative 
care would be missed out and that of all patients identified 
for such care 84% would die within 1 year.
The ProPal-COPD tool is the first which is using specific 
predictors of mortality during AECOPD requiring hospital-
izations. This tool relies on seven predictors: the surprise 
Total 406 Pt assessed for eligibility
Hospital 3
135 Pt assessed
Hospital 2
172 Pt assessed
Hospital 1
99 Pt assessed
60 Pt analyzed53 Pt analyzed
Total 155 Pt analyzed 
42 Pt analyzed
65 Pt considered64 Pt considered
Total 174 Pt considered
45 Pt considered
48 (17, 0, 31) Pt met exclusion criteria
1 (0, 1, 0) Pt died before consenting
183 (37, 107, 39) Pt refused
5 (1, 2, 2) Pt took part in other COPD-
related studies since inclusion date
1 (1, 0, 0) Pt had a lung transplant
13 (1, 9, 3) Pt had missing data
Figure 1 Participant flow diagram.
Abbreviation: Pt, patient.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
14
9 
on
 1
6-
O
ct
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2125
Development of the ProPal-COPD tool
question (a general predictor), five markers of COPD severity 
and the presence of specific comorbidities proven to indepen-
dently predict posthospital mortality in AECOPD.24 Through 
the surprise question, the tool incorporates clinical judgment 
of severity. The surprise question has shown to be a proven 
predictor of mortality in patients with advanced chronic 
diseases33 and is recommended to be used in combination 
with other disease-specific predictors as screening tool for 
proactive palliative care.23 Those disease-specific predictors 
in the ProPal-COPD tool are five markers of COPD severity 
being the CCQ (health status), MRC dyspnea, FEV
1
% 
of predicted value, body mass index (BMI) and previous 
hospitalizations for an AECOPD. The presence of one of 
the following comorbidities, non-curable malignancy, cor 
pulmonale, chronic heart failure (CHF) or diabetes mellitus 
with neuropathy or renal failure, is also incorporated in our 
tool. These comorbidities, except non-curable malignancy, 
are conditions liable to acute decompensation especially 
Table 2 Characteristics of the study population
Characteristics Mean ±SD
age, years 67.5 ±9.6
Pack years 36.4 ±32.8
n %
sex
Male 68 43.9
Marital status*
Married 110 71.0
Unmarried 11 7.1
Divorced 13 8.4
Widow 18 11.6
Condition of living*
single 34 21.9
non-single 111 71.6
Place of living*
home, independent of home care 103 66.5
home, dependent of home care 45 29.0
residential home 2 1.3
highest level of education*
no education 1 0.6
elementary school 21 13.5
secondary school 47 30.3
Primary education 35 22.6
secondary education 29 18.7
higher/university education 15 9.7
gOlD stage*,
0 8 5.2
I 10 6.5
II 41 26.5
III 52 33.5
IV 36 23.2
Predictors
hypoxemia or hypercapnia 62 40.0
nIV 11 7.1
Professional home care 50 32.3
negative answer sQ 76 49.0
Comorbidity 31 20.0
CCQ total, day version .3 96 61.9
MrC dyspnea =5 71 45.8
FeV1 ,30% of predicted 45 29.0
BMI ,21 or weight loss 26 16.8
Prev hosp aeCOPD 62 40.0
age .70 years 62 40.0
Notes: study population (n=155). *Because of missing values, some numbers do 
not add up to 100%. GOLD stage according to the last known data in medical file; 
inclusion in the study was based on the judgment by pulmonologist. 
Abbreviations: aeCOPD, acute exacerbation COPD; BMI, body mass index; 
CCQ, Clinical COPD Questionnaire; FeV1, forced expiratory volume in 1 second; 
gOlD, global Initiative for Chronic Obstructive lung Disease; MrC dyspnea, 
Medical research Council dyspnea questionnaire; nIV, noninvasive ventilation; prev 
hosp, previous hospitalization; sQ, surprise question.
Table 3 The discriminating power of individual predictors in 
predicting death within 1 year
Predictor Se Sp AUC
hypoxemia or hypercapnia 0.53 0.63 0.583
nIV 0.93 0.07 0.503
Professional home care 0.47 0.71 0.589
negative answer sQ 0.80 0.58 0.692
Comorbidity 0.43 0.86 0.645
CCQ total, day version .3 0.83 0.43 0.633
MrC dyspnea =5 0.80 0.62 0.712
FeV1 ,30% of predicted 0.43 0.64 0.589
BMI ,21 or weight loss 0.33 0.87 0.603
Previous hospitalization aeCOPD 0.60 0.65 0.624
age .70 years 0.43 0.61 0.521
Note: study population (n=155).
Abbreviations: aeCOPD, acute exacerbation COPD; aUC, area under the curve; 
BMI, body mass index; CCQ, Clinical COPD Questionnaire; FeV1, forced expiratory 
volume in 1 second; MrC dyspnea, Medical research Council dyspnea questionnaire; 
NIV, noninvasive ventilation; Se, sensitivity; Sp, specificity; SQ, surprise question.
Table 4 Optimal prediction model and its predictive performance 
of death within 1 year
Predictors in model B AUC True  
AUC
95% CI
Intercept -3.901
0.870 0.818 0.813–0.824
hypoxemia or hypercapnia /
nIV /
Professional home care /
negative answer sQ 0.959
Comorbidity 1.479
CCQ total, day version .3 0.257
MrC dyspnea =5 1.475
FeV1 ,30% of predicted 0.565
BMI ,21 or weight loss 1.005
Prev hosp aeCOPD 0.102
age .70 years /
Notes: study population (n=155). B, weight in the model. /, not incorporated in the 
optimal prediction model.
Abbreviations: aeCOPD, acute exacerbation COPD; aUC, area under the curve; 
BMI, body mass index; CCQ, Clinical COPD Questionnaire; CI, confidence interval; 
FeV1, forced expiratory volume in 1 second; MrC dyspnea, Medical research 
Council dyspnea questionnaire; nIV, noninvasive ventilation; prev hosp, previous 
hospitalization; sQ, surprise question.
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during AECOPD, which may explain their association with 
an increased mortality risk.16
Most predictors of the ProPal-COPD tool are variables 
already used in clinical practice and do not need extra 
measurement.34 Only the surprise question, the CCQ and 
MRC dyspnea, which are short easy-to-use questionnaires, 
are often not documented and need to be specifically asked 
for.34 Besides, each predictor in our tool has an own weight 
(B). Those weights take into account the correlation with 
other predictors of the tool and therefore should not be 
interpreted as the individual importance of each predictor 
in the tool. Moreover, the Lasso method used for model 
development is looking for the most efficient model.30 In the 
trade-off between efficiency and effectiveness, four predic-
tors (hypoxemia or hypercapnia, noninvasive ventilation 
[NIV], professional home care and age) were excluded from 
our optimal prediction model. This does not mean that those 
predictors were not predictive of death within 1 year. If we 
look at the predictor NIV, for example, it was noticeable that 
only 11 patients met the criteria of this predictor. Besides, 
NIV as an individual predictor had high sensitivity (0.93) and 
low specificity (0.07), meaning that almost all patients who 
were treated with NIV died within 1 year but patients who 
were not treated with NIV also had a considerable risk of 
dying. The exclusion of the predictor NIV can therefore be 
explained by the limited number of patients involved and the 
high correlation with predictors incorporated in our optimal 
prediction model. The other three predictors, hypoxemia or 
hypercapnia, professional home care and age, were merely 
excluded because of correlation.
The ProPal-COPD tool shows promise for the identifica-
tion of patients with COPD in need of proactive palliative 
care. The ROC analysis suggests that it has good prognos-
tic performance with a prognostic capacity superior to the 
CODEX index (comorbidity, age, obstruction, dyspnea and 
previous exacerbations).35 The CODEX index has an AUC 
of 0.68 in predicting death within 1 year and is the only 
other multivariable model developed to evaluate posthospital 
prognosis in patients with an AECOPD.35 However, the main 
objective of both tools is different. Our tool was developed to 
identify patients in need of proactive palliative care, whereas 
the CODEX was developed to predict mortality and/or read-
missions. In addition, there are several substantive differ-
ences. First, our tool incorporates disease-specific predictors 
of mortality in AECOPD requiring hospitalization, whereas 
the CODEX index was developed using disease-specific 
predictors of mortality in stable COPD. Second, our tool con-
tains specific comorbidities proven to independently predict 
posthospital mortality in AECOPD, whereas the evidence of 
the Charlson index (comorbidity burden) used in the CODEX 
index in predicting posthospital mortality in AECOPD is less 
consistent.16 Finally, each predictor in our tool has an own 
weight (B) in contrast to the predictors in the CODEX index. 
Those weights do not represent the individual importance of 
each predictor since they take into account the correlation 
with other predictors in the tool. Still, the own contribution of 
each predictor is better represented in our tool. It is possible 
that the abovementioned substantive differences between the 
ProPal tool and the CODEX index have contributed to the 
better prognostic performance of our tool.
Our study has several limitations that should be acknowl-
edged. First, predicting posthospital mortality for patients 
with COPD is complex and this is reflected by the number 
of potential predictors incorporated in the original set of 
predictors. We only used already known predictors in this set 
and it is uncertain if all possible predictors were accounted for. 
In addition, it is possible that certain predictors were under-
represented in the set of potential predictors. Anxiety and 
Prediction of death within 1 year,
with optimal cutoffs
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Figure 2 The rOC curve for the prediction of death within 1 year with the optimal 
cutoffs considering different trade-offs between se and sp.
Abbreviations: ROC, receiver operating characteristic; Se, sensitivity; Sp, specificity.
Table 5 Possible cutoffs considering different trade-offs between 
se and sp of the optimal prediction model
Cutoff Se Sp Se + Sp 1.5 Se + Sp
-1.105 0.800 0.840 1.640 2.040
-2.896 0.967 0.328 1.295 1.778
-2.169 0.933 0.504 1.437 1.904
-1.362 0.900 0.728 1.628 2.078
Abbreviations: Se, sensitivity; Sp, specificity.
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depression, for example, were represented as a subscale of the 
predictor CCQ. Second, to facilitate implementation in clini-
cal practice, we used dichotomized variables. Each potential 
predictor was given a clinical cutoff value based on literature. 
Such dichotomization of continuous predictors may lead to 
loss of information and reduction in power.36 Third, the use 
of the ProPal-COPD tool may require collection of data that 
are not always captured routinely (surprise question, CCQ, 
MRC dyspnea). Fourth, the ProPal-COPD tool was devel-
oped in the Netherlands. International differences in hospital 
admission policy for patients with an AECOPD may affect 
the usefulness in other countries. Fifth, it is unknown whether 
the ProPal-COPD tool is also applicable in academic hospitals 
since it was developed using a population of patients in gen-
eral hospitals. Finally, the ProPal-COPD tool was developed 
in a single population without validation in a different one. 
The external validity of our findings is therefore unknown 
and needs to be addressed in further research. Hence, other 
participant data need to be collected in a new prospective 
study performed in general and/or academic hospitals to 
evaluate the performance of the ProPal-COPD tool.
Conclusion
The ProPal-COPD tool is a promising tool to identify patients 
with COPD for proactive palliative care with good discrimi-
nating power (AUC =0.82). It relies on seven predictors: 
the surprise question (a general predictor), five markers of 
COPD severity and the presence of specific comorbidities. 
The prediction of death within 1 year was used as a proxy 
for the potential need of proactive palliative care. To ensure 
minimal miss out of patients in need of proactive palliative 
care, we proposed a cutoff in the prediction model that pri-
oritized sensitivity over specificity. This optimal cutoff has a 
sensitivity of 0.90 and a specificity of 0.73. Each predictor in 
the tool has an own weight and the patient can be considered 
in need of proactive palliative care only when the total sum of 
the model exceeds the specific cutoff point. This prognostic 
equation can be easily integrated in the electronic patient 
record (EPR) system. However, before clinical use of the 
ProPal-COPD tool, the external validity should be addressed 
in further research.
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